特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

悪性中皮腫:パイプライン製品の分析

Malignant Mesothelioma - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 229749
出版日 ページ情報 英文 1024 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
悪性中皮腫:パイプライン製品の分析 Malignant Mesothelioma - Pipeline Review, H1 2020
出版日: 2020年03月31日 ページ情報: 英文 1024 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

悪性胸膜中皮腫は、高いレベルのアスベストに暴露された人に見られる稀な癌です。悪性腫瘍によって、胸膜(肺と胸郭の内側を覆う滑らかな薄い細胞膜)が影響を受けます。腹膜中皮腫は腹部に起源するため、腹痛、体重減少、悪心、嘔吐がよく見られます。貧血、腸閉塞、胸痛、喀血なども含まれます。

当レポートでは、悪性中皮腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

悪性中皮腫の概要

治療薬の開発

  • パイプライン製品:概要
  • 開発中の治療薬:企業別
  • 調査中の治療薬:大学/研究機関別
  • 開発中の製品:企業別
  • 調査中の製品:大学/研究機関別

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Malignant Mesothelioma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Malignant Mesothelioma - Pipeline by AbbVie Inc, H1 2020
  • Malignant Mesothelioma - Pipeline by Agios Pharmaceuticals Inc, H1 2020
  • Malignant Mesothelioma - Pipeline by Akeso Biopharma Inc, H1 2020
  • Malignant Mesothelioma - Pipeline by Aldeyra Therapeutics Inc, H1 2020
  • Malignant Mesothelioma - Pipeline by Almac Discovery Ltd, H1 2020
  • Malignant Mesothelioma - Pipeline by Amphera BV, H1 2020
  • Malignant Mesothelioma - Pipeline by AnGes Inc, H1 2020
  • Malignant Mesothelioma - Pipeline by Apollomics Inc, H1 2020
  • Malignant Mesothelioma - Pipeline by Applied Research using OMIC Sciences SL, H1 2020
  • Malignant Mesothelioma - Dormant Projects, H1 2020
  • Malignant Mesothelioma - Discontinued Products, H1 2020
  • Malignant Mesothelioma - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Malignant Mesothelioma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12054IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2020, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 43, 37, 25, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 6 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
    • Malignant Mesothelioma - Overview
    • Malignant Mesothelioma - Therapeutics Development
    • Malignant Mesothelioma - Therapeutics Assessment
    • Malignant Mesothelioma - Companies Involved in Therapeutics Development
    • Malignant Mesothelioma - Drug Profiles
    • Malignant Mesothelioma - Dormant Projects
    • Malignant Mesothelioma - Discontinued Products
    • Malignant Mesothelioma - Product Development Milestones
    • Appendix